drugset / Trial / NCT03947320

Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.

NCT03947320

Phase 3 Unknown 70 enrolled Sinocelltech Ltd.
NaSingle-groupOpen-labelPrevention

Summary

This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (\<12 years old) with severe hemophilia A who have been previously treated with coagulation factor VIII(FVIII) . This study includes two phases: the screening period and prophylaxis period.Prophylaxis with 25 - 50 IU/kg of SCT800 shall be administered once every other day or three times per week starting from Visit 1 and prophylaxis with SCT800 shall continue for 24 consecutive weeks.

Timeline

Start
2019-12-20
Primary completion
2020-09-20
Completion
2020-09-20

Drugs

EvaluationDrugModalityDoseRoute
Subject SCT800 Protein / enzyme biologic 25 iu/kg Other
Subject SCT800 Protein / enzyme biologic 50 iu/kg Other

Indications